In reply to Drs Bowes and Crook

摘要

To the Editor: We appreciate this opportunity to respond to Drs Bowes and Crook.The first paragraph of the Bowes and Crook (B&C) response to our editorial (1) on dose escalation and prostate cancer is notable in that it says nothing about dose escalation. However, it contains questionable statements that deserve clarification.First, the Albertsen et al report of 2005 (2) correlates disease-specific mortality (DSM) with age, Gleason score, and time post-diagnosis (Table 1). These data do not suggest that DSM "is rare within 5-10 years of diagnosis" or that "the death toll is inexorable" beyond this time.